Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30565562 | 1.00 | CYP17A1 (0.38) | CYP17A1ATRMEN1NPC1GAA | |
| SCHEMBL26839479 | 0.88 | GSK3B (0.39) | CYP17A1ATRMEN1NPC1GAA | |
| SCHEMBL8162669 | 0.81 | CYP1A2 (0.42) | CYP17A1ATRNPC1RAB9AKMT2A | |
| SCHEMBL29442854 | 0.81 | LMNA (0.53) | CYP17A1ATRGAAKMT2AMAPT | |
| SCHEMBL15202941 | 0.81 | LMNA (0.53) | CYP17A1ATRGAAKMT2AMAPT | |
| SCHEMBL31709687 | 0.79 | NPC1 (0.39) | CYP17A1ATRMEN1NPC1GAA | |
| SCHEMBL31656043 | 0.79 | CYP17A1 (0.39) | CYP17A1ATRMEN1NPC1GAA | |
| SCHEMBL30986515 | 0.79 | CYP17A1 (0.36) | CYP17A1ATRKMT2AMAPTCA2 | |
| SCHEMBL30986333 | 0.78 | GLS (0.46) | CYP17A1GLS | |
| SCHEMBL24824441 | 0.77 | GLS (0.43) | CYP17A1GLSSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346602-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | DICE ALPHA INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4525987-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023225664-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225664-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-1145616-C | Novel amino-triazole compound, its preparation method and drug composition containing them | ɪά��ʵ���� | 2004-04-14 | — | — | CN | disclosed |
| US-6596749-B2 | Neuropeptide y receptor ligand | LES LABORATOIRES SERVIER (FR) | 2003-07-22 | — | — | US | disclosed |
| CN-1085663-C | Aromatic amino ethers as analgesic agents | ZENECA LTD (GB) | 2002-05-29 | — | — | CN | disclosed |
| US-20010018522-A1 | Aminotriazole compounds | LES LABORATOIRES SERVIER (FR) | 2001-08-30 | — | — | US | disclosed |
| US-6245916-B1 | USEFUL AS NEUROPEPTIDE Y RECEPTOR LIGANDS, ANXIOLYTIC AGENTS, SEDATIVES, AND VASOCONSTRICTORS | ADIR ET COMPAGNIE (FR) | 2001-06-12 | — | — | US | disclosed |
| CN-1286254-A | Aromatic amino ethers as analgesic agents | ZENECA LTD (GB) | 2001-03-07 | — | — | CN | disclosed |
| CN-1272493-A | Novel amino-triazole compound, its preparation method and drug composition containing them | ADIR (FR) | 2000-11-08 | — | — | CN | disclosed |
| CN-1154106-A | Aromatic amino ethers as analgesic agents | ZENECA LTD (GB) | 1997-07-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346602-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | IL17A, IL15, IL18 | CYP17A1 87/4885ATR 4446/4885MEN1 4711/4885 |
| US-20010018522-A1 | Aminotriazole compounds | NPY1R, NPY2R, NPY4R | CYP17A1 1124/4885ATR 1566/4885MEN1 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.